Logo of brjcancerBJC HomepageBJC Advance online publicationBJC Current IssueSubmitting an article to BJCWeb feeds
Br J Cancer. 1989 Jun; 59(6): 943–947.
PMCID: PMC2246720

Ki67 immunostaining in primary breast cancer: pathological and clinical associations.


Ki67 immunostaining has been performed on 136 primary breast cancers and related to various clinical and pathological features of the disease. Staining was most frequently seen in poorly differentiated tumours showing high rates of mitotic activity, but was independent of tumour size, lymph-node status and ER expression. A high level of Ki67 immunostaining was often associated with early recurrence of breast cancer after mastectomy. These data are consistent with the concept of the Ki67 antibody detecting an antigen that is closely related to cell proliferation and thus provides a clinically useful marker for this important characteristic of the tumour.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.0M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Images in this article

Click on the image to see a larger version.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Baisch H, Gerdes J. Simultaneous staining of exponentially growing versus plateau phase cells with the proliferation-associated antibody Ki-67 and propidium iodide: analysis by flow cytometry. Cell Tissue Kinet. 1987 Jul;20(4):387–391. [PubMed]
  • Barnard NJ, Hall PA, Lemoine NR, Kadar N. Proliferative index in breast carcinoma determined in situ by Ki67 immunostaining and its relationship to clinical and pathological variables. J Pathol. 1987 Aug;152(4):287–295. [PubMed]
  • Blamey RW, Bishop HM, Blake JR, Doyle PJ, Elston CW, Haybittle JL, Nicholson RI, Griffiths K. Relationship between primary breast tumor receptor status and patient survival. Cancer. 1980 Dec 15;46(12 Suppl):2765–2769. [PubMed]
  • Cooke T. The clinical application of oestrogen receptor analysis in early cancer of the breast. Ann R Coll Surg Engl. 1982 May;64(3):165–170. [PMC free article] [PubMed]
  • Gerdes J, Dallenbach F, Lennert K, Lemke H, Stein H. Growth fractions in malignant non-Hodgkin's lymphomas (NHL) as determined in situ with the monoclonal antibody Ki-67. Hematol Oncol. 1984 Oct-Dec;2(4):365–371. [PubMed]
  • Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol. 1984 Oct;133(4):1710–1715. [PubMed]
  • Gerdes J, Lelle RJ, Pickartz H, Heidenreich W, Schwarting R, Kurtsiefer L, Stauch G, Stein H. Growth fractions in breast cancers determined in situ with monoclonal antibody Ki-67. J Clin Pathol. 1986 Sep;39(9):977–980. [PMC free article] [PubMed]
  • Haag D, Goerttler K, Tschahargane C. The proliferative index (PI) of human breast cancer as obtained by flow cytometry. Pathol Res Pract. 1984 Mar;178(4):315–322. [PubMed]
  • Haybittle JL, Blamey RW, Elston CW, Johnson J, Doyle PJ, Campbell FC, Nicholson RI, Griffiths K. A prognostic index in primary breast cancer. Br J Cancer. 1982 Mar;45(3):361–366. [PMC free article] [PubMed]
  • Lellé RJ, Heidenreich W, Stauch G, Gerdes J. The correlation of growth fractions with histologic grading and lymph node status in human mammary carcinoma. Cancer. 1987 Jan 1;59(1):83–88. [PubMed]
  • Meyer JS, Lee JY. Relationships of S-phase fraction of breast carcinoma in relapse to duration of remission, estrogen receptor content, therapeutic responsiveness, and duration of survival. Cancer Res. 1980 Jun;40(6):1890–1896. [PubMed]
  • Silvestrini R, Sanfilippo O, Tedesco G. Kinetics of human mammary carcinomas and their correlation with the cancer and the host characteristics. Cancer. 1974 Oct;34(4):1252–1258. [PubMed]
  • Tubiana M, Pejovic MJ, Renaud A, Contesso G, Chavaudra N, Gioanni J, Malaise EP. Kinetic parameters and the course of the disease in breast cancer. Cancer. 1981 Mar 1;47(5):937–943. [PubMed]
  • Valeriote F, van Putten L. Proliferation-dependent cytotoxicity of anticancer agents: a review. Cancer Res. 1975 Oct;35(10):2619–2630. [PubMed]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK


Save items

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...


  • MedGen
    Related information in MedGen
  • PubMed
    PubMed citations for these articles

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...